Amivantamab–Lazertinib Combo Bests Osimertinib’s OS

Johnson & Johnson announced today that the combination of amivantamab (Rybrevant) and lazertinib (Lazcluze) showed a significant overall survival (OS) improvement compared with osimertinib (Tagrisso; AstraZeneca) in patients with non–small cell lung cancer (NSCLC) with EGFR exon 19 deletions or L858R substitution mutations in the phase III MARIPOSA study. Amivantamab is a bispecific mAb targeting EGFR and MET, and lazertinib and osimertinib are both EGFR inhibitors; osimertinib is the standard-of-care for newly diagnosed patients with EGFR-mutated NSCLC. The relative improvement in median OS is expected to exceed 1 year, according to the company, which will report the specifics at an upcoming major medical meeting. Researchers already reported that patients receiving the combination had a median progression-free survival of 23.7 months, compared with 16.6 months in patients who received osimertinib (Cancer Discov 2023;13:OF9).